For CDKN2B, there are still contradictory results, ranging from no correlation between promoter hypermethylation and breast cancer risk (Qi and Xiong, 2018) to an early and frequent event of breast carcinogenesis (Jung et al., 2013). The gene discussed is CDKN2B; the disease is breast cancer.